Hydronidone capsules
Sponsors
Beijing Continent Pharmaceutical Co, Ltd.
Conditions
Chronic Hepatitis B With Hepatic FibrosisChronic Hepatitis B-related Liver FibrosisLiver FibrosisRenal Insufficiency Chronic
Phase 1
A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency
RecruitingNCT07262333
Start: 2025-12-25End: 2026-12-01Target: 56Updated: 2026-08-13
The Phase Ⅰd Clinical Trial of Hydronidone Capsules
Not yet recruitingNCT07262346
Start: 2025-12-05End: 2026-05-05Target: 138Updated: 2025-12-03
Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls
CompletedNCT07394309
Start: 2026-03-25End: 2026-05-11Updated: 2026-08-13
Phase 2
A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis
CompletedNCT07364448
Start: 2026-03-12End: 2026-06-22Updated: 2026-08-13
A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis
CompletedNCT07417553
Start: 2026-04-15End: 2026-07-27Updated: 2026-08-13
Phase 3
Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.
CompletedNCT05115942
Start: 2021-12-30End: 2024-10-22Updated: 2024-12-20
Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
RecruitingNCT05905172
Start: 2023-08-12End: 2028-10-20Target: 248Updated: 2025-06-04
A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis
CompletedNCT07343778
Start: 2026-03-16End: 2026-07-28Updated: 2026-08-13